Mitochondrial neuroprotection in traumatic brain injury: Rationale and therapeutic strategies

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 4, 2014, Pages 606-619

  Yokobori, Shoji ^a,b   Mazzeo, Anna T ^c   Gajavelli, Shyam ^a   Bullock, Malcolm R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Apoptosis; Astrocyte neuron lactate shuttle; Cyclosporine A; Mitochondrial dysfunction; Mitochondrial permeability transition pore; Secondary brain injury; Traumatic brain injury

Indexed keywords

4' CHLORODIAZEPAM; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CATALASE; CATHEPSIN B INHIBITOR; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOSPORIN A; ERYTHROPOIETIN; GLUTAMATE RECEPTOR; GLUTATHIONE TRANSFERASE; HYPOXIA INDUCIBLE FACTOR 1; MAGNESIUM; MANGANESE SUPEROXIDE DISMUTASE; MICRORNA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; N ACETYLASPARTIC ACID; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PYRIDINE NUCLEOTIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; STAT3 PROTEIN; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; CYCLOSPORIN; LACTIC ACID; NEUROPROTECTIVE AGENT;

APOPTOSIS; ASTROCYTE NEURON LACTATE SHUTTLE HYPOTHESIS; COGNITION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HOMEOSTASIS; HUMAN; HYPOTHESIS; ISCHEMIC PRECONDITIONING; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; MITOCHONDRIAL DYSFUNCTION; MITOCHONDRIAL NEUROPROTECTION; MITOCHONDRIAL RESPIRATION; NEUROPROTECTION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRAUMATIC BRAIN INJURY; ANIMAL; BRAIN INJURIES; DRUG EFFECTS; METABOLISM; MITOCHONDRION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN INJURIES; CYCLOSPORINE; HUMANS; LACTIC ACID; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84904500326     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152731304140702112805     Document Type: Review

References (136)

1. Langlois JA, Marr A, Mitchko J, Johnson RL. Tracking the silent epidemic and educating the public: CDC's traumatic brain injuryassociated activities under the TBI Act of 1996 and the Children's Health Act of 2000. J Head Trauma Rehabil 2005; 20(3): 196-204.
2. Binder S, Corrigan JD, Langlois JA. The public health approach to traumatic brain injury: an overview of CDC's research and programs. J Head Trauma Rehabil 2005; 20(3): 189-95.
3. Fu ES, Tummala RP. Neuroprotection in brain and spinal cord trauma. Curr Opin Anaesthesiol 2005; 18(2): 181-7.
4. Vink R, Nimmo AJ. Multifunctional drugs for head injury. Neurotherapeutics 2009; 6(1): 28-42.
5. Gaetz M. The neurophysiology of brain injury. Clin Neurophysiol 2004; 115(1): 4-18.
6. Soustiel JF, Sviri GE. Monitoring of cerebral metabolism: nonischemic impairment of oxidative metabolism following severe traumatic brain injury. Neurol Res 2007; 29(7): 654-60.
7. Vespa P, Bergsneider M, Hattori N, et al. Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab 2005; 25(6): 763-74.
8. Signoretti S, Marmarou A, Aygok GA, et al. Assessment of mitochondrial impairment in traumatic brain injury using highresolution proton magnetic resonance spectroscopy. J Neurosurg 2008; 108(1): 42-52.
9. Mazzeo AT, Beat A, Singh A, Bullock MR. The role of mitochondrial transition pore, and its modulation, in traumatic brain injury and delayed neurodegeneration after TBI. Exp Neurol 2009; 218(2): 363-70.
10. Clausen T, Bullock R. Medical treatment and neuroprotection in traumatic brain injury. Curr Pharm Des 2001; 7(15): 1517-32.
11. Waldmeier PC, Zimmermann K, Qian T, Tintelnot-Blomley M, Lemasters JJ. Cyclophilin D as a drug target. Curr Med Chem 2003; 10(16): 1485-506.
12. Gilmer LK, Roberts KN, Joy K, Sullivan PG, Scheff SW. Early mitochondrial dysfunction after cortical contusion injury. J Neurotrauma 2009; 26(8): 1271-80.
13. Pellerin L, Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 1994; 91(22): 10625-9.
14. Aubert A, Costalat R, Magistretti PJ, Pellerin L. Brain lactate kinetics: Modeling evidence for neuronal lactate uptake upon activation. Proc Natl Acad Sci USA 2005; 102(45): 16448-53.
15. Kasischke KA, Vishwasrao HD, Fisher PJ, Zipfel WR, Webb WW. Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis. Science 2004; 305(5680): 99-103.
16. Porras OH, Loaiza A, Barros LF. Glutamate mediates acute glucose transport inhibition in hippocampal neurons. J Neurosci 2004; 24(43): 9669-73.
17. Pellerin L, Stolz M, Sorg O, et al. Regulation of energy metabolism by neurotransmitters in astrocytes in primary culture and in an immortalized cell line. Glia 1997; 21(1): 74-83.
18. Loaiza A, Porras OH, Barros LF. Glutamate triggers rapid glucose transport stimulation in astrocytes as evidenced by real-time confocal microscopy. J Neurosci 2003; 23(19): 7337-42.
19. Simard JM, Kent TA, Chen M, Tarasov KV, Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol 2007; 6(3): 258-68.
20. Kawamata T, Katayama Y, Hovda DA, Yoshino A, Becker DP. Lactate accumulation following concussive brain injury: the role of ionic fluxes induced by excitatory amino acids. Brain Res 1995; 674(2): 196-204.
21. Yokobori S, Watanabe A, Matsumoto G, et al. Time course of recovery from cerebral vulnerability after severe traumatic brain injury: a microdialysis study. J Trauma 2011; 71(5): 1235-40.
22. Bullock R, Zauner A, Myseros JS, et al. Evidence for prolonged release of excitatory amino acids in severe human head trauma. Relationship to clinical events. Ann NY Acad Sci 1995; 765: 290-7.
23. Goodman JC, Valadka AB, Gopinath SP, Cormio M, Robertson CS. Lactate and excitatory amino acids measured by microdialysis are decreased by pentobarbital coma in head-injured patients. J Neurotrauma 1996; 13(10): 549-56.
24. Inao S, Marmarou A, Clarke GD, et al. Production and clearance of lactate from brain tissue, cerebrospinal fluid, and serum following experimental brain injury. J Neurosurg 1988; 69(5): 736-44.
25. Zauner A, Doppenberg EM, Woodward JJ, et al. Continuous monitoring of cerebral substrate delivery and clearance: initial experience in 24 patients with severe acute brain injuries. Neurosurgery 1997; 41(5): 1082-91.
26. Zauner A, Doppenberg E, Woodward JJ, et al. Multiparametric continuous monitoring of brain metabolism and substrate delivery in neurosurgical patients. Neurol Res 1997; 19(3): 265-73.
27. Zhao QJ, Zhang XG, Wang LX. Mild hypothermia therapy reduces blood glucose and lactate and improves neurologic outcomes in patients with severe traumatic brain injury. J Crit Care 2011; 26(3): 311-5.
28. Siegel JH, Rivkind AI, Dalal S, Goodarzi S. Early physiologic predictors of injury severity and death in blunt multiple trauma. Arch Surg 1990; 125(4): 498-508.
29. Rehncrona S, Rosen I, Siesjo BK. Brain lactic acidosis and ischemic cell damage: 1. Biochemistry and neurophysiology. J Cereb Blood Flow Metab 1981; 1(3): 297-311.
30. Siesjo BK. Cell damage in the brain: a speculative synthesis. J Cereb Blood Flow Metab 1981; 1(2): 155-85.
31. Bergersen LH. Is lactate food for neurons? Comparison of monocarboxylate transporter subtypes in brain and muscle. Neuroscience 2007; 145(1): 11-9.
32. Andersen BJ, Marmarou A. Post-traumatic selective stimulation of glycolysis. Brain Res 1992; 585(1-2): 184-9.
33. Andersen BJ, Marmarou A. Functional compartmentalization of energy production in neural tissue. Brain Res 1992; 585(1-2): 190-5.
34. Valadka AB, Goodman JC, Gopinath SP, Uzura M, Robertson CS. Comparison of brain tissue oxygen tension to microdialysis-basedmeasures of cerebral ischemia in fatally head-injured humans. J Neurotrauma 1998; 15(7): 509-19.
35. Vespa PM, McArthur D, O'Phelan K, et al. Persistently low extracellular glucose correlates with poor outcome 6 months after human traumatic brain injury despite a lack of increased lactate: a microdialysis study. J Cereb Blood Flow Metab 2003; 23(7): 865-77.
36. Nelson DW, Thornquist B, MacCallum RM, et al. Analyses of cerebral microdialysis in patients with traumatic brain injury: relations to intracranial pressure, cerebral perfusion pressure and catheter placement. BMC Med 2011; 9: 21.
37. Friess SH, Ralston J, Eucker SA, et al. Neurocritical care monitoring correlates with neuropathology in a swine model of pediatric traumatic brain injury. Neurosurgery 2011; 69(5): 1139-47.
38. Chen T, Qian YZ, Di X, et al. Lactate/glucose dynamics after rat fluid percussion brain injury. J Neurotrauma 2000; 17(2): 135-42.
39. Yuan XQ, Wade CE. Lactated Ringer's solution alleviates brain trauma-precipitated lactic acidosis in hemorrhagic shock. J Neurotrauma 1993; 10(3): 307-13.
40. Schurr A, Payne RS, Miller JJ, Rigor BM. Glia are the main source of lactate utilized by neurons for recovery of function posthypoxia. Brain Res 1997; 774(1-2): 221-4.
41. Levasseur JE, Alessandri B, Reinert M, et al. Lactate, not glucose, upregulates mitochondrial oxygen consumption both in sham and lateral fluid percussed rat brains. Neurosurgery 2006; 59(5): 1122-30.
42. Holloway R, Zhou Z, Harvey HB, et al. Effect of lactate therapy upon cognitive deficits after traumatic brain injury in the rat. Acta Neurochir (Wien) 2007; 149(9): 919-27.
43. Gallagher CN, Carpenter KL, Grice P, et al. The human brain utilizes lactate via the tricarboxylic acid cycle: a 13C-labelled microdialysis and high-resolution nuclear magnetic resonance study. Brain 2009; 132(Pt 10): 2839-49.
44. Rice AC, Zsoldos R, Chen T, et al. Lactate administration attenuates cognitive deficits following traumatic brain injury. Brain Res 2002; 928(1-2): 156-9.
45. Green D, Kroemer G. The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol 1998; 8(7): 267-71.
46. Ankarcrona M, Dypbukt JM, Bonfoco E, et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 1995; 15(4): 961-73.
47. Sullivan PG, Rabchevsky AG, Waldmeier PC, Springer JE. Mitochondrial permeability transition in CNS trauma: cause or effect of neuronal cell death? J Neurosci Res 2005; 79(1-2): 231-9.
48. Lifshitz J, Sullivan PG, Hovda DA, Wieloch T, McIntosh TK. Mitochondrial damage and dysfunction in traumatic brain injury. Mitochondrion 2004; 4(5-6): 705-13.
49. Fiskum G. Mitochondrial participation in ischemic and traumatic neural cell death. J Neurotrauma 2000; 17(10): 843-55.
50. Starkov AA, Chinopoulos C, Fiskum G. Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. Cell Calcium 2004; 36(3-4): 257-64.
51. Xiong Y, Gu Q, Peterson PL, Muizelaar JP, Lee CP. Mitochondrial dysfunction and calcium perturbation induced by traumatic brain injury. J Neurotrauma 1997; 14(1): 23-34.
52. Singh IN, Sullivan PG, Deng Y, Mbye LH, Hall ED. Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy. J Cereb Blood Flow Metab 2006; 26(11): 1407-18.
53. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 1998; 60: 619-42.
54. Robertson CL, Scafidi S, McKenna MC, Fiskum G. Mitochondrial mechanisms of cell death and neuroprotection in pediatric ischemic and traumatic brain injury. Exp Neurol 2009; 218(2): 371-80.
55. Stavrovskaya IG, Kristal BS. The powerhouse takes control of the cell: is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death? Free Radic Biol Med 2005; 38(6): 687-97.
56. Sullivan PG, Rabchevsky AG, Hicks RR, et al. Dose-response curve and optimal dosing regimen of cyclosporin A after traumatic brain injury in rats. Neuroscience 2000; 101(2): 289-95.
57. Sullivan PG, Thompson M, Scheff SW. Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury. Exp Neurol 2000; 161(2): 631-7.
58. Sullivan PG, Keller JN, Mattson MP, Scheff SW. Traumatic brain injury alters synaptic homeostasis: implications for impaired mitochondrial and transport function. J Neurotrauma 1998; 15(10): 789-98.
59. Robertson CL, Saraswati M, Fiskum G. Mitochondrial dysfunction early after traumatic brain injury in immature rats. J Neurochem 2007; 101(5): 1248-57.
60. Soane L, Kahraman S, Kristian T, Fiskum G. Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders. J Neurosci Res 2007; 85(15): 3407-15.
61. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995; 1241(2): 139-76.
62. Szabo I, Zoratti M. The giant channel of the inner mitochondrial membrane is inhibited by cyclosporin A. J Biol Chem 1991; 266(6): 3376-9.
63. Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimie 2002; 84(2-3): 153-66.
64. Tsujimoto Y, Shimizu S. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 2007; 12(5): 835-40.
65. Kristal BS, Stavrovskaya IG, Narayanan MV, et al. The mitochondrial permeability transition as a target for neuroprotection. J Bioenerg Biomembr 2004; 36(4): 309-12.
66. Greco T, Fiskum G. Neuroprotection through stimulation of mitochondrial antioxidant protein expression. J Alzheimers Dis 2010; 20(Suppl 2): S427-37.
67. Greco T, Shafer J, Fiskum G. Sulforaphane inhibits mitochondrial permeability transition and oxidative stress. Free Radic Biol Med 2011; 51(12): 2164-71.
68. Jung JE, Kim GS, Narasimhan P, Song YS, Chan PH. Regulation of Mn-superoxide dismutase activity and neuroprotection by STAT3 in mice after cerebral ischemia. J Neurosci 2009; 29(21): 7003-14.
69. Zhao X, Sun G, Zhang J, et al. Transcription factor Nrf2 protects the brain from damage produced by intracerebral hemorrhage. Stroke 2007; 38(12): 3280-6.
70. Dash PK, Zhao J, Orsi SA, Zhang M, Moore AN. Sulforaphane improves cognitive function administered following traumatic brain injury. Neurosci Lett 2009; 460(2): 103-7.
71. Scafidi S, Racz J, Hazelton J, McKenna MC, Fiskum G. Neuroprotection by acetyl-L-carnitine after traumatic injury to the immature rat brain. Dev Neurosci 2010; 32(5-6): 480-7.
72. Sullivan PG, Thompson MB, Scheff SW. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. Exp Neurol 1999; 160(1): 226-34.
73. Okonkwo DO, Povlishock JT. An intrathecal bolus of cyclosporine A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury. J Cereb Blood Flow Metab 1999; 19(4): 443-51.
74. Okonkwo DO, Buki A, Siman R, Povlishock JT. Cyclosporin A limits calcium-induced axonal damage following traumatic brain injury. Neuroreport 1999; 10(2): 353-8.
75. Shiga Y, Onodera H, Matsuo Y, Kogure K. Cyclosporin A protects against ischemia-reperfusion injury in the brain. Brain Res 1992; 595(1): 145-8.
76. Matsumoto S, Friberg H, Ferrand-Drake M, Wieloch T. Blockade of the mitochondrial permeability transition pore diminishes infarct size in the rat after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab 1999; 19(7): 736-41.
77. Uchino H, Elmer E, Uchino K, et al. Amelioration by cyclosporine A of brain damage in transient forebrain ischemia in the rat. Brain Res 1998; 812(1-2): 216-26.
78. Uchino H, Elmer E, Uchino K, Lindvall O, Siesjo BK. Cyclosporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischaemia in the rat. Acta Physiol Scand 1995; 155(4): 469-71.
79. Friberg H, Ferrand-Drake M, Bengtsson F, Halestrap AP, Wieloch T. Cyclosporin A, but not FK 506: protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J Neurosci 1998; 18(14): 5151-9.
80. Ferrand-Drake M, Zhu C, Gido G, et al. Cyclosporin A prevents calpain activation despite increased intracellular calcium concentrations, as well as translocation of apoptosis-inducing factor, cytochrome c and caspase-3 activation in neurons exposed to transient hypoglycemia. J Neurochem 2003; 85(6): 1431-42.
81. Signoretti S, Marmarou A, Tavazzi B, et al. The protective effect of cyclosporin A upon N-acetylaspartate and mitochondrialdysfunction following experimental diffuse traumatic brain injury. J Neurotrauma 2004; 21(9): 1154-67.
82. Povlishock JT, Pettus EH. Traumatically induced axonal damage: evidence for enduring changes in axolemmal permeability with associated cytoskeletal change. Acta Neurochir Suppl 1996; 66: 81-6.
83. Alessandri B, Rice AC, Levasseur J, et al. Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion injury in rats. J Neurotrauma 2002; 19(7): 829-41.
84. Li PA, Kristian T, He QP, Siesjo BK. Cyclosporin A enhances survival, ameliorates brain damage, and prevents secondary mitochondrial dysfunction after a 30-minute period of transient cerebral ischemia. Exp Neurol 2000; 165(1): 153-63.
85. Kilbaugh TJ, Bhandare S, Lorom DH, et al. Cyclosporin A preserves mitochondrial function after traumatic brain injury in the immature rat and piglet. J Neurotrauma 2011; 28(5): 763-74.
86. Colley BS, Phillips LL, Reeves TM. The effects of cyclosporin-A on axonal conduction deficits following traumatic brain injury in adult rats. Exp Neurol 2010; 224(1): 241-51.
87. Hatton J, Rosbolt B, Empey P, Kryscio R, Young B. Dosing and safety of cyclosporine in patients with severe brain injury. J Neurosurg 2008; 109(4): 699-707.
88. Mazzeo AT, Brophy GM, Gilman CB, et al. Safety and tolerability of cyclosporin a in severe traumatic brain injury patients: results from a prospective randomized trial. J Neurotrauma 2009; 26(12): 2195-206.
89. Mazzeo AT, Kunene NK, Gilman CB, et al. Severe human traumatic brain injury, but not cyclosporin a treatment, depresses activated T lymphocytes early after injury. J Neurotrauma 2006; 23(6): 962-75.
90. Mazzeo AT, Alves OL, Gilman CB, et al. Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: a microdialysis study. Acta Neurochir (Wien) 2008; 150(10): 1019-31.
91. Lulic D, Burns J, Bae EC, van Loveren H, Borlongan CV. A review of laboratory and clinical data supporting the safety and efficacy of cyclosporin A in traumatic brain injury. Neurosurgery 2011; 68(5): 1172-85.
92. Sullivan PG, Sebastian AH, Hall ED. Therapeutic window analysis of the neuroprotective effects of cyclosporine A after traumatic brain injury. J Neurotrauma 2011; 28(2): 311-8.
93. Petronilli V, Penzo D, Scorrano L, Bernardi P, Di Lisa F. The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ. J Biol Chem 2001; 276(15): 12030-4.
94. Hansson MJ, Mansson R, Mattiasson G, et al. Brain-derived respiring mitochondria exhibit homogeneous, complete and cyclosporin-sensitive permeability transition. J Neurochem 2004; 89(3): 715-29.
95. Mattiasson G, Friberg H, Hansson M, Elmer E, Wieloch T. Flow cytometric analysis of mitochondria from CA1 and CA3 regions of rat hippocampus reveals differences in permeability transition pore activation. J Neurochem 2003; 87(2): 532-44.
96. Lemasters JJ, Nieminen AL, Qian T, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998; 1366(1-2): 177-96.
97. Clausen T, Zauner A, Levasseur JE, Rice AC, Bullock R. Induced mitochondrial failure in the feline brain: implications for understanding acute post-traumatic metabolic events. Brain Res 2001; 908(1): 35-48.
98. Nakai A, Shibazaki Y, Taniuchi Y, et al. Role of mitochondrial permeability transition in fetal brain damage in rats. Pediatr Neurol 2004; 30(4): 247-53.
99. Panickar KS, Jayakumar AR, Norenberg MD. Differential response of neural cells to trauma-induced free radical production in vitro. Neurochem Res 2002; 27(1-2): 161-6.
100. Mirzayan MJ, Klinge PM, Ude S, et al. Modified calcium accumulation after controlled cortical impact under cyclosporin A treatment: a 45Ca autoradiographic study. Neurol Res 2008; 30(5): 476-9.
101. Scorrano L, Ashiya M, Buttle K, et al. A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Dev Cell 2002; 2(1): 55-67.
102. Hansson MJ, Morota S, Chen L, et al. Cyclophilin D-sensitive mitochondrial permeability transition in adult human brain and liver mitochondria. J Neurotrauma 2011; 28(1): 143-53.
103. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003; 112(4): 481-90.
104. Stoica B, Byrnes K, Faden AI. Multifunctional drug treatment in neurotrauma. Neurotherapeutics 2009; 6(1): 14-27.
105. Vink R, Nimmo AJ. Novel therapies in development for the treatment of traumatic brain injury. Exp Opin Investig Drugs 2002; 11(10): 1375-86.
106. Lee JS, Han YM, Yoo DS, et al. A molecular basis for the efficacy of magnesium treatment following traumatic brain injury in rats. J Neurotrauma 2004; 21(5): 549-61.
107. Turkyilmaz C, Turkyilmaz Z, Atalay Y, Soylemezoglu F, Celasun B. Magnesium pre-treatment reduces neuronal apoptosis in newborn rats in hypoxia-ischemia. Brain Res 2002; 955(1-2): 133-7.
108. Maas AI, Murray GD. Magnesium for neuroprotection after traumatic brain injury. Lancet Neurol 2007; 6(1): 20-1.
109. Moore EM, Bellomo R, Nichol AD. Erythropoietin as a novel brain and kidney protective agent. Anaesth Intens Care 2011; 39(3): 356-72.
110. Mammis A, McIntosh TK, Maniker AH. Erythropoietin as a neuroprotective agent in traumatic brain injury Review. Surg Neurol 2009; 71(5): 527-31.
111. Xiong Y, Chopp M, Lee CP. Erythropoietin improves brain mitochondrial function in rats after traumatic brain injury. Neurol Res 2009; 31(5): 496-502.
112. Zhao J, Li G, Zhang Y, Su X, Hang C. The potential role of JAK2/STAT3 pathway on the anti-apoptotic effect of recombinant human erythropoietin(rhEPO) after experimental traumatic brain injury of rats. Cytokine 2011; 56(2): 343-50.
113. Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 2004; 22(2): 105-19.
114. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009; 40(12): e647-56.
115. Papadopoulos V, Lecanu L. Translocator protein(18 kDa) TSPO: an emerging therapeutic target in neurotrauma. Exp Neurol 2009; 219(1): 53-7.
116. Papadopoulos V, Lecanu L, Brown RC, Han Z, Yao ZX. Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders. Neuroscience 2006; 138(3): 749-56.
117. Veenman L, Papadopoulos V, Gavish M. Channel-like functions of the 18-kDa translocator protein(TSPO): regulation of apoptosis and steroidogenesis as part of the host-defense response. Curr Pharm Des 2007; 13(23): 2385-405.
118. Parker MA, Bazan HE, Marcheselli V, Rodriguez de Turco EB, Bazan NG. Platelet-activating factor induces permeability transition and cytochrome c release in isolated brain mitochondria. J Neurosci Res 2002; 69(1): 39-50.
119. Guicciardi ME, Leist M, Gores GJ. Lysosomes in cell death. Oncogene 2004; 23(16): 2881-90.
120. Krysko DV, Vanden Berghe T, D'Herde K, Vandenabeele P. Apoptosis and necrosis: detection, discrimination and phagocytosis. Methods 2008; 44(3): 205-21.
121. Luo CL, Chen XP, Yang R, et al. Cathepsin B contributes to traumatic brain injury-induced cell death through a mitochondria-mediated apoptotic pathway. J Neurosci Res 2010; 88(13): 2847-58.
122. Correia SC, Carvalho C, Cardoso S, et al. Mitochondrial preconditioning: a potential neuroprotective strategy. Front Aging Neurosci 2010; 2: 138.
123. Correia SC, Santos RX, Perry G, et al. Mitochondria: the missing link between preconditioning and neuroprotection. J Alzheimers Dis 2010; 20(Suppl 2): S475-85.
124. Janoff A. Alterat Ions in Lysosomes (Intracellular Enzymes) during Shock; Effects of Preconditioning (Tolerance) and Protective Drugs. Int Anesthesiol Clin 1964; 2: 251-69.
125. Perez-Pinzon MA. Neuroprotective effects of ischemic preconditioning in brain mitochondria following cerebral ischemia. J Bioenerg Biomembr 2004; 36(4): 323-7.
126. Davis DP, Patel PM. Ischemic preconditioning in the brain. Curr Opin Anaesthesiol 2003; 16(5): 447-52.
127. Dirnagl U, Becker K, Meisel A. Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. Lancet Neurol 2009; 8(4): 398-412.
128. Kottenberg E, Thielmann M, Bergmann L, et al. Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial. Acta Anaesthesiol Scand 2012; 56(1): 30-8.
129. Ravati A, Ahlemeyer B, Becker A, Krieglstein J. Preconditioninginduced neuroprotection is mediated by reactive oxygen species. Brain Res 2000; 866(1-2): 23-32.
130. Saugstad JA. MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection, and neurodegeneration. J Cereb Blood Flow Metab 2010; 30(9): 1564-76.
131. Zhang JH, Lo T, Mychaskiw G, Colohan A. Mechanisms of hyperbaric oxygen and neuroprotection in stroke. Pathophysiology 2005; 12(1): 63-77.
132. Hu S, Li F, Luo H, et al. Amelioration of rCBF and PbtO2 following TBI at high altitude by hyperbaric oxygen preconditioning. Neurol Res 2010; 32(2): 173-8.
133. Longhi L, Gesuete R, Perego C, et al. Long-lasting protection in brain trauma by endotoxin preconditioning. J Cereb Blood Flow Metab 2011; 31(9): 1919-29.
134. Costa T, Constantino LC, Mendonca BP, et al. N-methyl-Daspartate preconditioning improves short-term motor deficits outcome after mild traumatic brain injury in mice. J Neurosci Res 2010; 88(6): 1329-37.
135. Maas AI, Roozenbeek B, Manley GT. Clinical trials in traumatic brain injury: past experience and current developments. Neurotherapeutics 2010; 7(1): 115-26.
136. Pellerin L, Magistretti PJ. Sweet sixteen for ANLS. J Cereb Blood Flow Metab 2012; 32(7): 1152-66.